112 results
Page 4 of 6
8-K
EX-10.1
wktz iupg3
7 Dec 20
Entry into a Material Definitive Agreement
6:05am
8-K
EX-2.1
afe5w hvv2tk5u14c60
7 Dec 20
Entry into a Material Definitive Agreement
6:05am
8-K
EX-99.2
jur2iqa
7 Dec 20
Entry into a Material Definitive Agreement
6:05am
8-K
vrueq8ew01d8lufepcd
7 Dec 20
Entry into a Material Definitive Agreement
6:05am
8-K
EX-99.1
dqxek 0w4ibgovzb
26 Oct 20
Syros Presents Initial Data from Phase 1 Clinical Trial of SY-5609, Its Selective Oral
6:10am
8-K
n47wf2l
26 Oct 20
Syros Presents Initial Data from Phase 1 Clinical Trial of SY-5609, Its Selective Oral
6:10am
8-K
EX-99.1
4ud5z9m
13 Feb 20
Syros Announces $60 Million Loan Facility with Oxford Finance LLC
8:51am
8-K
EX-99.2
pib8qry87bm4m9xczd9
13 Jan 20
Regulation FD Disclosure
6:11am
8-K
EX-99.1
f3m tyy5iz
13 Jan 20
Regulation FD Disclosure
6:11am
8-K
EX-99.1
r7ykiym
2 Dec 19
Regulation FD Disclosure
7:03am
8-K
EX-99.1
uo5e223d838ta2
24 Oct 19
62% Composite Complete Response Rate, with 82% of Patients Achieving or Maintaining Transfusion Independence
8:36am
8-K
fls9fiemcr uu7mazx
24 Oct 19
62% Composite Complete Response Rate, with 82% of Patients Achieving or Maintaining Transfusion Independence
8:36am